Thursday, September 9, 2010

The Changing Landscape of Biosimilars

The most recent issue of Pharmaceutical Technology Europe, they profile the landscape of biosimilars. In this issue they cover The Biosimilars Market of Today and Tomorrow, A SWOT analysis of the biosimilars market, Latest EU Guidelines, Launching and Commercializing Biosimilars and more. To discuss any of these articles in depth, join our Business of Biosimilars LinkedIn group where over 300 professionals around the world discussing the latest news and information in biosimilars.

Share this article with your social network, just click below to share now!

1 comment :

Unknown said...

Though biosimilars are highly valued for their effectiveness as treatments, the costs-per-patient of many biologics are often significant and sometimes can be prohibitive. As all countries tussle with the issues of access to biologics and other medicines while confronting increasingly limited health care resources; achievement of the full potential of biosimilars is becoming increasingly challanging. My collegues and I recently authored one of the most indepth reports on the Biosimilars industry in India. If anyone is interested in this, feel free to write to me at Ashritha.

Post a Comment